November 2006, Volume 56, Issue 11

Review Articles

Obstetric Cerebral Venous Thrombosis

Abstract

 

Pregnancy and puerperium are most prevalent prothrombotic states leading to cerebral venous thrombosis. Likelihood of stroke to be of venous origin is greater in stroke associated with pregnancy compared to stroke unrelated to pregnancy. Pregnancy induces several changes in coagulation system, which persists at least during early puerperium, rendering it a prothrombotic state. Hypercoaguability worsens further after delivery as a result of volume depletion and trauma. During puerperium additional risk factors include infection and instrumental delivery or Caesarean section. The management follows general rules as for the venous thrombosis unrelated to pregnancy, however the prognosis is different.

Introduction

Pregnancy and puerperium are well established causes of venous thromboembolism (VTE), including intracranial venous thrombosis.1,2 Several physiological changes in coagulation system render pregnancy and puerperium prothrombotic states.3-8 Since every woman of reproductive age has potential to become pregnant and hence is at risk of cerebral venous thrombosis (CVT). The association was first described by Abercrombie in 1828 and latter by Collier.9,10 It is important to discuss the association since no factor is as prevalent as pregnancy. However, not every pregnant woman develops CVT and it (along with puerperium) accounts for only 20% of cases.11,12 Further more the entity may be more common in developing world.13,14 We will discuss physiology of coagulation system during pregnancy, epidemiology of obstetric CVT (CVT during pregnancy and puerperium), its pathophysiology, clinical features, management and prognosis.

Coagulation during pregnancy and puerperium

Changes in coagulation system i.e. enhancement of procoagulants and inhibition of anticoagulants, during pregnancy are considered to be physiological adaptations of the body in order to face the haemostatic challenge of delivery. Significant changes include reduction in protein S levels, rise in activated protein C (APC) resistance, increments in fibrinogen, plasminogen activator inhibitors (PAI), prothrombin fragments 1 and 2 (F 1+2), and coagulant activity of factors V and VIII.

Protein S (total and free) begins to fall around 10 weeks of gestation and continue to fall through out pregnancy.3,4,7 The protein S activity falls by approximately 50% compared to normal controls.3,4 Resistance to APC increases through out pregnancy and at term seen in more than half of normal pregnant women compared to normal non pregnant controls.3,5 Interestingly no reduction occurs in absolute levels of protein C, rather it increases during early postpartum period.3,7 Similarly no change occurs in antithrombin (AT) levels.3 Resistance to APC has been attributed to rise in factors V and VIII.3 The Factor V activity increases after 16 weeks of gestation and the activity increases by 29% at term.3 Fibrinogen levels start to rise as early as 6-7 weeks and continue to rise thereafter.4 From 20th week onwards prothrombin time shortens, probably as a result of increased levels of factor VII.4 Changes in protein S, resistance to APC, factors V and VIII, and fibrinogen persist during puerperium, at least a few days.3-6 The levels of F1+2 rise through out pregnancy and fall during puerperium.3 Fibrinolytic system is inhibited by elevation of PAI-1 during 3rd trimester.4

Platelets play a very important role in coagulation. Their concentration remains same during pregnancy.

However their aggregating ability increases. In addition their responsiveness to prostacyclin and cAMP formation is reduced. Over all these changes favor coagulation.8
Epidemiology of obstetric CVT

Pregnancy and puerperium are important risk factors for CVT and European researchers have reported that it accounts for about 20% of all CVT cases.11,12 However, literature from developing countries revealed a higher proportion of obstetric CVT. In his series of 113 patients, Cantu C et al from Mexico reported that obstetric CVT accounted for 59% of the cases.9 The estimated annual incidence of CVT (overall) is 3-4 cases per million population and 75% adult patients are women.11,15 Using National hospital discharge survey data from US (1979-1991), Lanska DJ et al estimated risk of peripartum CVT about 8.9/100,000 deliveries.16 The risk is even higher i.e. 11.4/100,000 deliveries for entire period of pregnancy.17 Recently data from healthcare cost and utilization project (1993-1994) revealed a risk of 11.6/100,000 deliveries for peripartum intracranial venous thrombosis.18 The entity is more common in developing countries. Bansal et al, from India, reported prevalence of 4.5/1000 obstetric cases during early 80s.14 In their autopsy series, Banerjee K et al during late 80s, found that CVT accounts for approximately 10% of all strokes.19 Recently Panagariya et al from India reported that CVT accounts for half of all young strokes and 40% of strokes in women.20

Despite the fact that pregnancy and puerperium increase risk of both venous and arterial stroke the proportion of venous stroke is much higher in pregnancy related stroke as compared to stroke unrelated to pregnancy.2 Jiann-Shing et al from Taiwan reported that in women of 15-40 years of age, with first ever stroke- proportion of CVT is 39% in pregnancy related stroke as compared to only 5% in pregnancy unrelated stroke.2

CVT usually presents either late in pregnancy or puerperium but cases have been reported as early as 8 weeks.21 Majority of studies have reported a higher proportion of CVT during puerperium compared to pregnancy. However, US literature reported more or less similar proportion.16-18 The ratio of CVT during puerperium and pregnancy is reported to be 2.1:1 to 3.25:1 from European countries and 13:1 to 14:1 from developing countries like Mexico and India.9,11,12,20 Higher risk during puerperium has been attributed to bad obstetrical practices i.e. home deliveries by untrained dais and restriction of water early after delivery.20

Pathogenesis and Risk Factors of obstetric CVT

Hypercoaguability plays an important role in development of CVT during pregnancy and puerperium. As mentioned earlier several changes occur in coagulation system, which are more marked during the third trimester, and render it a hypercoaguable state. In addition dehydration as a result blood loss during delivery and bad obstetric practices and local trauma during delivery worsen the prothrombotic state. The hypercoaguability and venous stasis as a result of prolonged bed rest, instrumental delivery or Caesarean section will lead to thrombosis.12 Occlusion of cerebral veins lead to cytotoxic and vasogenic edema, and infarction while occlusion of major sinuses leads to intracranial hypertension.15

In addition to these pathophysiologic processes and factors, several other risk factors have also been noted by various investigators.

Cantu et al noted significantly higher proportion of anaemia and ESR in puerperal cases compared to non puerperal cases.9 A significant association has constantly been found with young age from developing as well as developed countries.14,16-18 Lanska et al reported that younger group 14-25 years is more vulnerable.16,17 In a series of 138 cases from India, 112 were under 30 years of age.14 Caesarean section and infections have been found to be independent risk factors of obstetric CVT and they increase the risk by three times.18 Caesarean section may increase the risk by postsurgical decline of protein C levels, presumably because surgically induced tissue damage induces the activation of blood clotting with increased thrombin generation, which in turn both activates protein C and accelerates its clearance from plasma.22 Pregnancy induced hypertension and excessive vomiting have also been reported to contribute independently in development of obstetric CVT.17 Multiparity has been over represented in obstetric CVT, from developing countries.9,13,14,20 Bansal et al reported a statistically significant rise in serum triglycerides, phospholipids, free fatty acids, blood platelet count, platelet adhesive index, and fall in blood fibrinolytic activity as compared to normal controls.20

Several isolated cases of pregnancy associated CVT have been reported in whom other risk factors were documented so it is wise to remember other risk factors e.g. homocysteinemia, hypercoaguable states (protein C deficiency, factor V Leiden, mutations in prothrombin gene 20201), vasculitic and other inflammatory processes, trauma and drugs.23-25

Clinical features

Major clinical features of obstetric CVT are similar to CVT unrelated to pregnancy. These include headache, focal deficits, seizures and mental status changes. However, certain important differences have been noted by Cantu et al.9 They found more acute course and early stabilization. They also noted lesser frequency of motor findings and generalized seizures, and higher frequency of focal seizures at presentation. However, during the course of disease the differences in frequency of seizure type and motor deficits vanish.9 Mental status changes especially somnolence/ drowsiness were more common in obstetric CVT.9 On the contrary isolated intracranial hypertension was more frequent in CVT unrelated to pregnancy.9

Differential Diagnosis

It is important to differentiate this condition from other pregnancy associated central nervous system (CNS) disorders i.e eclampsia and postpartum cerebral angiopathy. It is also important to exclude arterial strokes, parenchymal haemorrhages unrelated to CVT, subarachnoid haemorrhage (SAH) and CNS infections.

Diagnosis

Most important diagnostic test is MRI and MRV of brain. LP may be needed to exclude CNS infection. Work up for hypercoaguability, especially genetic disorders-, inflammatory and vasculitic disorders is required in selected cases.

Management

Management of obstetric CVT is not different from that of CVT unrelated to pregnancy. Hence it includes supportive care, seizure control, measures to lower intracranial pressure, search and treatment of possible infection. To prevent further thrombosis, anticoagulation is the preferred treatment, currently. This is based on a few small randomized trials and extensive anecdotal experience.26,27 Local thrombolysis has also been tried in conjunction with systemic intravenous heparin, with encouraging results.28,29 Except Indians none have reported on anticoagulation specifically in obstetric CVT. Srinivasan used heparin in uncontrolled fashion in 80s and noted that mortality was lower amongst heparin group.13 Recently Nagaraja et al conducted two randomized controlled trials of low dose (2500 units thrice daily) unfractionated subcutaneous heparin in contrast to high dose heparin infusion or low molecular weight heparin, used in earlier trials in patients with obstetric CVT and found it beneficial.30,31 The first trial published in 1995 and heparin was used only in patients with CVT with out any haemorrhage.29 Second trial published in Neurology India in 1999 includes all patients with puerperal CVT irrespective of the haemorrhage.30 This trial includes 73 patients in heparin group (27 with haemorrhagic stroke) and 77 in control group (27 with haemorrhagic stroke). Complete recovery was seen in 34 (47%) patients in treatment arm as compared to 14 (18%) in control group and mortality was 8 (11%) vs. 18 (23%). This is an important and encouraging therapeutic trial. However it is limited by its design as it was not a placebo controlled double blind trial and by the fact that higher proportion of patients in control arm had status epilepticus which might have contributed to higher mortality in control arm.

Prognosis

Prognosis of CVT is quite variable and the outcome ranges from total recovery to death. The disease had a fatal outcome during preimaging era, when neither early diagnosis was feasible/possible nor effective therapies and supportive care was available.

Various obstetric CVT series have reported a mortality rate from 4-33% (Table 1).9,11,13,20,31-33

Table 1. Mortality of CVT associated with pregnancy and puerperium^*
[(0)]
^Year= year of publication, N= total number of patients in the series
*Percentages in parenthesis
†21 countries from Europe, Canada, Australia and Latin America

Cantu et al reported lower mortality i.e. 9.7 vs. 32.6% in Obstetric CVT. However proportion of complete recovery was similar in both the groups.

Favourable outcome has been reported from 60-76% of cases.9,33 Favorable outcome in obstetric CVT has been attributed to the assumption that the occlusion is limited and transient with rapid recanalization or by development of collaterals.9

Neuropsychiatric manifestations and pseudotumor cerebri like presentations carry favourable prognosis while acute fulminant course, bilateral haemorrhagic infarctions and diffuse cerebral oedema are associated with relatively poor outcome.20

There is no data on long term outcome including recurrence during subsequent pregnancy in patients with obstetric CVT. However, Mehraein et al reported that there is no substantial risk of CVT during subsequent pregnancy in women who had CVT in past whether obstetric or not.34 In their retrospective review 14/39 women had 22 pregnancies and none developed CVT over a mean follow up of 10 years. These 14 women also included 4 women in whom index CVT was also pregnancy related event.34

Conclusion

Obstetric CVT is not uncommon. It must be considered in young women presenting with any neurologic manifestation related to CNS during pregnancy (especially 3rd trimester) and puerperium. Obstetric CVT has a different course and carries favourable prognosis as compared to CVT unrelated to pregnancy. There is evidence that mortality can be altered favourably by anticoagulation. The treatment of obstetric CVT is similar to CVT unrelated to pregnancy, including conventional anticoagulation. Low dose subcutaneous is viable/feasible and potentially efficacious option, however, this needs to be confirmed in controlled randomized trials.

References

1. National Institutes of health consensus development conference. Prevention of venous thrombosis and pulmonary embolism. JAMA 1986;256:744-9.

2. Jiann-Shing J, Sung-Chun T, Ping-Keung Y. Stroke in women of reproductive age:comparison between stroke related and unrelated to pregnancy. J Neurol Sci 2004;221:25-9.

3. Clark P, Brennand J, Conkie JAC, McCall F, Greer IA, Walker ID. Activated protein C sensitivity, protein C protein, S and coagulation in normal pregnancy. Thromb Haemostas 1998;79:1166-70.

4. Cerneca F, Ricci G, Simeone R, Malisano M, Alberico S, Guaschino S. Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. Eur J Obstet Gynaecol Reprod Biol 1997;73:31-6.

5. Cumming AM, Tait RC, Fildes S, Yoong A, Keeney S, Hay CRM. Development of resistance to activated protein C during pregnancy. Br J Haematol. 1995;90:725-7.

6. Bremme K, Ostlund E, Almqvist I, Heinonen K, Blomback M. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and puerperiuum. Obstet Gynecol 1992;80:132-7

7. Faught W, Garner P, Jones G, Ivey B. Changes in protein C and protein S levels in normal pregnancy. Am J Obstet Gynecol 1995;172:147-50.

8. Almagro Vazquez, delfina. La Hemostasia en el embarazo. Rev Cubana Hematol Inmunol Hemoter, Mayo-ago. 2000;16:90-8.

9. Cantu C C, Barinagarrementeria F. Cerebral venous thrombosis associated with pregnancy and puerperium: review of 67 cases. Stroke 1993;24:1880-4.

10. Collier W. Thrombosis of cerebral veins. Lancet 1891;1:544.

11. Ferro JM, Canhao P, Stam J, Bousser M-G, Barinagarrementeria F; for ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis:results of the international study on cerebral vein and dural sinus thrombosis (ISCVT). Stroke 2004;35:664-70.

12. Bouser M-G, Russell RR. Cerebral venous thrombosis. W B Saunders publishers. London. Ist edition 1997: pp 47-87.

13. Srinivasan K. Ischemic cerebrovascular disease in the young. Two common causes in India. Stroke 1984;15:733-5.

14. Bansal BC, Gupta RR, Prakash C. Stroke during pregnancy and puerperium in young females below the age of 40 years as a result of cerebral venous/venous sinus thrombosis. Jpn Heart J. 1980;21:171-83.

15. Stam J. Thrombosis of cerebral veins and sinuses. N Engl Med J 2005;352:1791-8.

16. Lanska DJ, Kryscio RJ. Peripartum stroke and intracranial venous thrombosis in the National Hospital Discharge Survey. Obstet Gynecol. 1997;89:413-18.

17. Lanska DJ, Kryscio RJ. Stroke and intracranial venous thrombosis during pregnancy and puerperium. Neurology 1998;51:1622-8.

18. Lanska DJ, Kryscio RJ. Risk Factors for Peripartum and Postpartum Stroke and Intracranial Venous Thrombosis Stroke. 2000;31:1274-82.

19. Banerjee AK, Varma M, Vasista RK, Chopra JS. Cerebrovascular disease in north-west India: a study of necropsy material. J Neurol Neurosurg Psychiatry 1989;52:512-5.

20. Panagariya A, Maru A. Cerebral venous thrombosis in pregnancy and puerperium--a prospective study. J Assoc Physicians India. 1997;45:857-9.

21. Lavin PJ, Bone I, Lamb JT, Swinburne LM. Intracranial venous thrombosis in the first trimester of pregnancy. J Neurol Neurosurg Psychiatry. 1978;41:726-9.

22. Bonnar J, Davidson JF, Pidgeon CF, McNicol GP, Douglas AS. Fibrin degradation products in normal and abnormal pregnancy and parturition. BMJ. 1969;3:137-40.

23. Derex L, Philippeau F, Nighoghossian N, Trouillas P, Berruyer M. Postpartum cerebral venous thrombosis, congenital protein C deficiency, and activated protein C resistance due to heterozygous factor V Leiden mutation. J Neurol Neurosurg psychiatry 1998;65:801-2.

24. Weih M, Mehraein S, Valdueza JM, Einhaupl KM, Vetter B, Kulozik AE. Coincidence of factor V Leiden mutation and prothrombin gene at position 20210 in a patient with puerperal cerebral venous thrombosis. Stroke 1998;29:1739-40.

25. Vignazia GL, La Mura F, Gaidano G, Della Corte F. Post gravidic superior sagittal sinus thrombosis with elevated levels of homocystinemia. Minerva Anestesiol 2004;70:831-6.

26. Einhaupl KM, Villringer A, Meister W, Meister W, Mehraein S, Garner C, Pellkofer M, Habert RL, Pfister HM, et al. Heparin in sinus venous thrombosis. Lancet 1991;338:597-600.

27. de Bruijn SFTM, Stam J, for cerebral venous sinus thrombosis study group. Randomized, placebo controlled trial of anticoagulant treatment with low molecular weight heparin for cerebral venous thrombosis. Stroke 1999;30:384-8.

28. Frey JL, Muro GJ, McDougall CG, Dean BL, Heidi KJ. Cerebral venous thrombosis; combined intrathrombus rtPA and intravenous heparin. Stroke 1999;30:489-4.

29. Wasay M, Bakshi R, Kojan S, Bobustuc G, Dubey N, Unwin DH. Nonrandomized comparison of local urokinase thrombolysis versus systemic heparin anticoagulation for superior sagittal sinus thrombosis. Stroke 2001;32:2310-7.

30. Nagaraja D, Rao BSS, Taly AB et al. Randomized controlled trial of heparin in puerperal cerebral venous thrombosis in India. 1999; 47 issue; pp 43-6.

31. Nagaraja D, Haridas T, Taly AB, Veerendrakumar M, Subbukrishna DK. Puerperal cerebral venous thrombosis: therapeutic benefit of low dose heparin. Neurol India; 1999;47:43-6.

32. Sanchetee PC, Dhaumija RM, Roy AK. Peripartum cerebral venous thrombosis. J Assoc Physicians India ; 1992 ;40 :664-6.

33. Mehraein S, Ortwein H, Busch M, Weih M, Einhaupl KM, Masuhr F. Risk of recurrence of cerebral venous and sinus thrombosis during subsequent pregnancy and puerperium. J Neurol Neurosurg Psychiatry 2003;74:814-6.

34. Hamouda M'Rad I. Marbet A, Ben Hamida. Thromboses veineuses et infarctus arterielis cerebraux au cours de la grossesse et du post-partum. Rev Neurol (Paris). 1995 ;151 :563-8.

Journal of the Pakistan Medical Association has agreed to receive and publish manuscripts in accordance with the principles of the following committees: